

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kasibhatla *et al.*

Appl. No. 10/046,548

Filed: January 16, 2002

For: **Methods of Identifying Potentially  
Therapeutically Selective and  
Effective Anti-Cancer Agents that  
are Inducers of Apoptosis**

Confirmation No. 1805

Art Unit: 1651

Examiner: Yu, M.

Atty. Docket: 1735.0610001/RWE/ALS

RECEIVED  
SEP 30 2003  
TECH CENTER 1600/2900

**First Supplemental Information Disclosure Statement**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on August 28, 2002, in connection with the above-captioned application. A copy of the cited document is also provided. The Examiner is respectfully requested to consider the cited document as well as the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates


should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. This First Supplemental Information Disclosure Statement is being filed prior to the mailing of a first office action on the merits. Accordingly, no fee is necessary. 37 C.F.R. § 1.97(b)(3). The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Aaron L. Schwartz  
Agent for Applicants  
Registration No. 48,181

Date: Sept 16, 2003

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

FIRST SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1735.0610001/RWE/ALSAPPLICATION NO.  
10/046,548APPLICANTS  
Kasibhatla et al.FILING DATE  
January 16, 2002GROUP  
1651RECEIVED  
SEP 30 2003  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK3	2002/0150885 A1	10/17/2002	Weber et al.			09/07/2001

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>1</u>	
	AS	<u>1</u>	
	AT	<u>1</u>	

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.